hrp0086wg5.5 | ESPE Diabetes Technology and Therapeutics Working Group | ESPE2016

Use of Dual Hormone (Glucagone) vs Single Hormone (Insulin) in the Treatment of Diabetes with Closed-loop System

Battelino Tadej

Dual hormone closed-loop insulin/glucagon delivery has been successfully used in in- and out-patient clinical setting with a reduction in hypoglycemia and improvement in time in range of glucose concentration. However, the main goal of the dual hormone closed-loop systems – complete prevention of hypoglycemia – has not been achieved. In the latest published studies with dual hormone closed-loop systems the amount of intervention with oral carbohydrates is still almos...

hrp0086fc13.4 | Management of Obesity | ESPE2016

Efficacy and Safety of Duodenal-Jejunal Bypass Liner in Morbidly Obese Adolescents-1 Year Experience

Kotnik Primoz , Homan Matjaz , Orel Rok , Battelino Tadej

Background: The duodenal-jejunal bypass liner (DJBL) is an endoscopically placed and removable bariatric device associated with weight loss and metabolic improvements in adults.Objective and hypotheses: To determined efficacy and safety of DJBL up to 1 year in morbidly obese adolescents.Method: About 14 obese adolescents with prediabetes or type 2 diabetes (10 female, mean (SD) age 17.7 (1.1) years) underwent endoscopic placement o...

hrp0084fc12.6 | Obesity - Clinical | ESPE2015

Initial Experience with Endoscopically Placed Duodenal–Jejunal Bypass Liner (Endobarrier) in Morbidly Obese Adolescents

Kotnik Primož , Homan Matjaž , Orel Rok , Battelino Tadej

Background: The duodenal–jejunal bypass liner (DJBL) is an endoscopically placed and removable intestinal liner that creates a duodenal–jejunal bypass. Weight loss and diabetes improvement was reported in the adults.Objective and hypotheses: To evaluate clinical effects and safety of this device in severely obese adolescents with obesity complications.Method: Six morbidly obese adolescents (four female, mean age 18.2 year...

hrp0095p1-108 | Growth and Syndromes | ESPE2022

Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial

Sävendahl Lars , Battelino Tadej , Højby Rasmussen Michael , Brod Meryl , Wai Lee Kai , Saenger Paul , Horikawa Reiko

Children with GHD are currently treated with daily subcutaneous growth hormone (GH) injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for once-weekly use in children with GHD. REAL 3 (NCT02616562) is a phase 2, multinational, randomised, open label, controlled trial assessing efficacy and safety of somapacitan vs daily GH (Norditropin®). Prepubertal, GH-naïve children with GHD received 0.04 (n=16), 0.08 (n</e...

hrp0089fc10.2 | Late Breaking | ESPE2018

Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial

Savendal Lars , Rasmussen Michael , Horikawa Reiko , Khadilkar Vaman , Battelino Tadej , Saenger Paul

Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden by patients and caregivers. Somapacitan is a long-acting GH derivative that is being developed for once-weekly dosing in adults and children with GHD. A well-established protraction method, which is successfully in use to extend the half-life of insulin and glucagon-like peptide (GLP)-1, has been applied in developing ...

hrp0089rfc9.2 | Pituitary, Neuroendocrinology and Puberty 1 | ESPE2018

Novel Variant in GNRHR Gene Regulatory Region in a Pedigree with Maternally Inherited Precocious Puberty

Stefanija Magdalena Avbelj , Kovač Jernej , Yablonski Galia , Phillip Moshe , Battelino Tadej , de Vries Liat

Background: Gonadotropin-releasing hormone (GNRH) and its receptor (GNRHR) are central regulators of puberty. Loss-of-function mutations of the GNRH-GNRHR signaling pathway are associated with congenital hypogonadotropic hypogonadism, but no mutations were reported so far in patients with central precocious puberty (CPP). Animal data demonstrate the importance of microRNAs in pubertal timing regulation. Among others, miR200b regulates Gnrh1 gene expression in GnRH neu...

hrp0089rfc15.6 | Growth and syndromes | ESPE2018

Latest Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment

Kanumakala Shankar , Pfaffle Roland , Hoybye Charlotte , Kristrom Berit , Battelino Tadej , Zabransky Markus , Zouater Hichem

Objectives: PATRO Children is a non-interventional, international, longitudinal study of the long-term safety of a recombinant human growth hormone (rhGH; Omnitrope®, Sandoz). In particular, the study will assess the diabetogenic potential of rhGH and the risk of malignancies. The long-term efficacy is a secondary objective of the study.Methods: The study population includes infants, children and adolescents receiving Omnitrope®...

hrp0089p2-p096 | Diabetes &amp; Insulin P2 | ESPE2018

The Incorporation of Available Technologies for Diabetes Care Among Different Worldwide Centers: The ESPE/ISPAD Working Group on Diabetes Technology Survey

Dovc Klemen , Shalitin Shlomit , Hanas Ragnar , Boughton Charlotte , Musolino Gianluca , Battelino Tadej , Nimri Revital , Phillip Moshe

Objective: International Societies for diabetes care are aiming to facilitate and improve the uptake of diabetes technologies. This survey investigated healthcare professional (HCP) evaluation of the role of technology in diabetes care within their centres.Methods: Between April to November 2017, 215 HCPs from six continents (132 Europe, 36 Asia, 23 North and 7 South America, 9 Africa and 8 Australasia) replied to an online survey and provided data for a...

hrp0086p1-p634 | Growth P1 | ESPE2016

Four-Year Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment

Pfaffle Roland , Kanumakala Shankar , Charlotte Hoybye , Berit Kristrom , Markus Zabransky , Tadej Battelino , Michel Colle

Background: PATRO Children is an international, open, longitudinal, non-interventional study of the long-term safety and efficacy of Omnitrope®, a biosimilar recombinant human GH (rhGH).Objective and hypotheses: The primary objective of PATRO Children is to assess long-term safety of Omnitrope® (particularly the diabetogenic potential of GH in short children born small for gestational age, the risk of malignancies, and oth...

hrp0086p1-p729 | Pituitary and Neuroendocrinology P1 | ESPE2016

Clinical and Mutational Spectrum in Slovenian Patients with Hypogonadotropic Hypogonadism

Stefanija Magdalena Avbelj , Obreza Tamara , Pfeifer Marija , Kovac Jernej , Battelino Tadej , Podkrajsek Katarina Trebusak

Background: Congenital hypogonadotropic hypogonadism (HH) is a rare but clinically and genetically heterogeneous disease characterized by an absent or incomplete puberty and infertility. The association of HH with hyposmia or anosmia is defined as Kallmann syndrome. Molecular genetic testing of HH is valuable, as it can prompt the treatment in adolescence.Objective and hypotheses: To identify causative variants in genes associated with HH in a cohort of ...